288617-73-2 Usage
Description
(S)-2-(((9H-FLUOREN-9-YL)METHOXY)CARBONYLAMINO)-2-METHYLHEPT-6-ENOIC ACID, commonly known as Fmoc-(S)-2-(4-pentenyl)Ala-OH, is a Fmoc-protected amino acid derivative that plays a crucial role in the synthesis of stapled peptides. (S)-2-(((9H-FLUOREN-9-YL)METHOXY)CARBONYLAMINO)-2-METHYLHEPT-6-ENOIC ACID is characterized by its unique structure, which includes a fluorenylmethoxycarbonylamino group and a 2-methylhept-6-enoic acid backbone. Its ability to participate in ring-closing metathesis reactions makes it a valuable component in the development of novel peptide-based therapeutics and research tools.
Uses
Used in Pharmaceutical Industry:
(S)-2-(((9H-FLUOREN-9-YL)METHOXY)CARBONYLAMINO)-2-METHYLHEPT-6-ENOIC ACID is used as a key building block for the synthesis of stapled peptides, which are a new class of therapeutic agents with enhanced stability and cell permeability. These peptides have the potential to modulate protein-protein interactions, which are often challenging to target with traditional small molecule drugs. The use of this compound in stapled peptide synthesis can lead to the development of innovative treatments for various diseases, including cancer and neurological disorders.
Used in Research and Development:
In the field of research and development, (S)-2-(((9H-FLUOREN-9-YL)METHOXY)CARBONYLAMINO)-2-METHYLHEPT-6-ENOIC ACID is utilized for creating diverse peptide libraries. These libraries are essential for high-throughput screening and the identification of novel bioactive peptides with potential applications in drug discovery, diagnostics, and therapeutics. (S)-2-(((9H-FLUOREN-9-YL)METHOXY)CARBONYLAMINO)-2-METHYLHEPT-6-ENOIC ACID's ability to form stable peptides through ring-closing metathesis reactions allows researchers to explore a wide range of peptide sequences and their corresponding biological activities.
Used in Drug Delivery Systems:
Similar to gallotannin, (S)-2-(((9H-FLUOREN-9-YL)METHOXY)CARBONYLAMINO)-2-METHYLHEPT-6-ENOIC ACID can also be employed in the development of advanced drug delivery systems. By incorporating this compound into the design of drug carriers, such as nanoparticles or liposomes, researchers can improve the delivery, bioavailability, and therapeutic outcomes of stapled peptides. This approach can enhance the efficacy of peptide-based drugs and potentially reduce their side effects by enabling targeted delivery to specific cells or tissues.
Shipping
Store below 5°C. Must be shipped over night on ice, additional shipping charges may incur. This product has a low melting point. When received, it may be an oil.
Check Digit Verification of cas no
The CAS Registry Mumber 288617-73-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,8,6,1 and 7 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 288617-73:
(8*2)+(7*8)+(6*8)+(5*6)+(4*1)+(3*7)+(2*7)+(1*3)=192
192 % 10 = 2
So 288617-73-2 is a valid CAS Registry Number.
InChI:InChI=1/C23H25NO4/c1-3-4-9-14-23(2,21(25)26)24-22(27)28-15-20-18-12-7-5-10-16(18)17-11-6-8-13-19(17)20/h3,5-8,10-13,20H,1,4,9,14-15H2,2H3,(H,24,27)(H,25,26)/t23-/m0/s1
288617-73-2Relevant articles and documents
A reappraisal of the Ni-[(Benzylprolyl)amino]benzophenone complex in the synthesis of α,α-disubstituted amino acid derivatives
Watson, Morag E.,Jamieson, Craig,Kennedy, Alan R.,Mason, Andrew M.
, (2019/08/08)
α,α-Disubstituted alkenyl amino acid derivatives (e.g. Fmoc-S5-OH) are valuable monomers in the construction of stapled peptide derivatives. Synthetic access to these is possible using the Ni-[(Benzylprolyl)amino]benzophenone (BPB) complex as a chiral auxiliary. We discuss a reappraisal of the use of this, and demonstrate that epimerisation of the proline α-centre occurs during formation of the complex, leading to erosion in the enantiomeric excess of the final product. Modified conditions have been developed, providing the target compounds in high enantiomeric excess.
Stabilized alpha helical peptides and uses thereof
-
, (2016/05/19)
Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
DISUBSTITUTED AMINO ACIDS AND METHODS OF PREPARATION AND USE THEREOF
-
Paragraph 0100; 0192; 0193, (2014/05/20)
Provided are crystalline α, α-disubstituted amino acids and their crystalline salts containing a terminal alkene on one of their side chains, as well as optionally crystalline halogenated and deuterated analogs of the α, α-disubstituted amino acids and their salts; methods of making these, and methods of using these.
